SAB Biotherapeutics (SABS) Interest & Investment Income (2021 - 2026)
SAB Biotherapeutics (SABS) posted Interest & Investment Income of $1.0 million for Q1 2026, up 49.44% on a QoQ basis from $700739.0 in Q4 2025, and up 1575.57% year-over-year from $62498.0 in Q1 2025.
SAB Biotherapeutics (SABS) Interest & Investment Income (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Interest & Investment Income history runs 6 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- Quarterly Interest & Investment Income rose 1575.57% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 184.12% YoY) and the FY2025 annual result came in at $1.4 million, up 11.36% from the prior year.
- Interest & Investment Income was $1.0 million for Q1 2026 at SAB Biotherapeutics, up from $700739.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.0 million in Q1 2026 and bottomed at $7933.0 in Q1 2022.
- A 5-year average of $260074.4 and a median of $62498.0 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 1829.64% — and 2025, when it tumbled 96.38%.
- SAB Biotherapeutics' Interest & Investment Income stood at $29929.0 in 2022, then jumped by 1517.31% to $484046.0 in 2023, then sank by 71.83% to $136374.0 in 2024, then surged by 413.84% to $700739.0 in 2025, then soared by 49.44% to $1.0 million in 2026.
- Business Quant data shows SABS's Interest & Investment Income at $1.0 million in Q1 2026, $700739.0 in Q4 2025, and $655233.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | SAB Biotherapeutics | 185.85 Mn | 185.85 Mn | - | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.05 Mn |
| Dec 31, 2025 | 700,739.00 |
| Sep 30, 2025 | 655,233.00 |
| Jun 30, 2025 | 13,562.00 |
| Mar 31, 2025 | 62,498.00 |
| Dec 31, 2024 | 136,374.00 |
| Sep 30, 2024 | 277,174.00 |
| Jun 30, 2024 | 374,557.00 |
| Mar 31, 2024 | 497,893.00 |
| Dec 31, 2023 | 484,046.00 |
| Sep 30, 2023 | 14,364.00 |
| Jun 30, 2023 | 28,568.00 |
| Mar 31, 2023 | 57,988.00 |
| Dec 31, 2022 | 29,929.00 |
| Sep 30, 2022 | 17,385.00 |
| Jun 30, 2022 | 15,824.00 |
| Mar 31, 2022 | 7,933.00 |
| Dec 31, 2021 | 8,544.00 |
| Sep 30, 2021 | 3,769.00 |
| Jun 30, 2021 | 5,296.00 |